House votes to designate October National Pharmacists Month
ALEXANDRIA, Va. October has been designated National Pharmacists Month by a unanimous vote in the U.S. House of Representatives, the National Community Pharmacists Association today announced. The passing of H.R. 1437 is a nod to the important role community pharmacists play in the delivery of health care in America.
“Keeping America healthy is a solemn obligation of pharmacists,” NCPA president and pharmacy owner, Stephen L. Giroux, said in a statement. “As experts on the frontlines of our health care system, pharmacists work tirelessly to educate their patients about their medications to ensure any illness, medical condition or disease is being fully addressed. We hope our partnerships with the public and private sector will only grow over time in order to improve the level of access and quality care patients receive.”
Giroux continued, thanking the House on behalf of more than 23,000 practicing pharmacists. “A special note of appreciation goes out to Representative Marion Berry (D-AR), the only pharmacist in Congress, who took the lead in getting this resolution passed unanimously,” he said.
More information on the designation can be found at www.ncpanet.org.
Independent pharmacy organization backs insurance coverage relief bill
ALEXANDRIA, Va. The National Community Pharmacists Association has joined with other groups representing smaller-scale employers to back new federal legislation that could ease the health insurance cost burdens on smaller businesses.
NCPA, the nation’s largest independent pharmacy organization, yesterday announced its endorsement of H.R. 6582, the Small Business Cooperative for Health Care Options to Improve Coverage for Employees [CHOICE] Act of 2008. The bill, introduced by U.S. House Small Business Committee chair Nydia Velazquez, D-N.Y., with support from both parties, is aimed at keeping smaller employers from falling prey to steadily rising health care and insurance costs.
To do so, the CHOICE bill creates private, voluntary purchasing cooperatives established under state insurance laws to provide excess claims insurance coverage to participating small businesses. The bill allows those employers to pool health risks over a larger number of insured plan participants, thus reducing costs and, ultimately, premiums.
H.R. 6582 also provides a refundable tax credit to small employers who purchase health insurance for their employees through the cooperative.
“With the cost of health insurance for small businesses rising 80 percent in the past eight years, the time for action has clearly arrived,” responded NCPA executive vice president and chief executive officer Bruce Roberts. The CHOICE bill, he added, “expands access to high-quality, affordable health insurance access for American small businesses and the self-employed. This bill provides the common-sense solutions to improve economic growth and productivity by promoting a healthier work force.”
Among other groups supporting the legislation: the American Optometric Association, American Rental Association, Coca-Cola Bottlers’ Association, Computing Technology Industry Association, International Franchise Association, National Association for Self-Employed, National Association of Home Builders, National Association of Realtors, National Black Chamber of Commerce, National Community Pharmacists Association, National Funeral Directors Association, National Gay & Lesbian Chamber of Commerce, National Restaurant Association, National Roofing Contractors Association, National Utility Contractors Association, U.S. Chamber of Commerce, U.S. Women’s Chamber of Commerce, and Women in Public Policy.
No connection between Lou Gehrig’s disease and statins, FDA says
WASHINGTON Cholesterol-lowering drugs do not increase the risk of Lou Gehrig’s disease, an analysis by the Food and Drug Administration has found.
The analysis, reported Monday in the journal Pharmacoepidemiology and Drug Safety, used data from 41 long-term controlled clinical trials involving statins. The FDA conducted the analysis after receiving an unusually large number of reports of Lou Gehrig’s disease in patients using the drugs in its Adverse Event Reporting System, but did not find an increase in the number of statin patients with the disease compared with those taking a placebo.
“The FDA’s review, which began in 2007, is an example of the agency working to analyze products [throughout their lifecycle] to keep healthcare professionals and patients informed of new and emerging safety data,” said Dr. Mark Avignan, director of the Division of Pharmacovigilance I at the FDA’s Center for Drug Evaluation and Research.
Lou Gehrig’s disease is the common name for amyotrophic lateral sclerosis, or ALS. It causes a gradual weakening of the muscles and impairment of speech ability.